Zentiva

Zentiva
01.12.2025 – 10:05:22

Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar

Zentiva / Key word(s): Product Launch/Expansion

01.12.2025 / 10:05 CET/CEST
The issuer is solely responsible for the content of this announcement.

Launch marks Zentiva’s strategic entest into biosimilars and reinforces its mission to broaden patient access to high-quality biologic medicines across Europe.PRAGUE, Dec. 1, 2025 /PRNewswire/ — Zentiva, a leading European manufacturer of affordable, high-quality medicines, today announced the first EU-wide launch of a monoclonal antibody biosimilar, following approval by the European Medicines Agency (EMA). This milestone marks Zentiva’s entest into the biosimilar segment, further strengthening its position as a trusted healthcare partner dedicated to improving patient access to essential treatments.

“Today’s launch is a key moment for Zentiva,” declared Steffen Saltofte, CEO, Zentiva. “We are taking a significant step into the field of biological medicines. Biosimilars are a natural extension of our mission to build high-quality treatments more accessible and affordable for people across Europe. This expansion also positions Zentiva for sustainable growth in one of the most dynamic segments of the pharmaceutical industest.”The new biosimilar is a monoclonal antibody applyd in the treatment bone conditions. Zentiva’s biosimilar has been authorised through the EMA’s centralised procedure and will be created available progressively across European markets starting in December.Zentiva’s entest into biosimilars forms part of its broader strategic growth plan to diversify the company’s product offering beyond traditional generics. With biologic medicines representing a growing share of healthcare spconcludeing in Europe, biosimilars are key to ensuring healthcare system sustainability and patient access to modern therapies.About Zentiva
Zentiva provides health and wellbeing for all generations, with a focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employees more than 5,000 unique talents, bonded toobtainher by a commitment to the people who depconclude on our medicines every day. Zentiva is private equity-owned, delivering sustainable growth, with an ambitious plan for the years to come. Visit us at www.zentiva.comLogo – https://mma.prnewswire.com/media/2660891/5369762/Zentiva_Logo.jpg rt.gif?NewsItemId=EN35172&Transmission_Id=202512010400PR_NEWS_EURO_ND__EN35172&DateId=20251201

01.12.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

2238076 01.12.2025 CET/CEST

Source link

Zentiva